Status: Recruiting
Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases
This is an investigator-initiated trial to evaluate the efficacy and safety of BCMA/CD70-targeted CAR-T in the treatment of refractory pediatric rheumatic diseases.
Participants needed: 11
Trial details
Phase: Phase 1Age: 5+Biological sex: AllType: InterventionalSponsor: Chongqing Precision Biotech Co., LtdUpdated: Sep 19, 2025Locations: 1
Eligibility criteria
Age ≥5 years old. [+18]
Severe major organ involvement related to the primary disease, such as severe pu... [+10]